Palvella Therapeutics, Inc. (PVLA) Return on Equity (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Return on Equity for 11 consecutive years, with 0.0% as the latest value for Q3 2024.
- On a quarterly basis, Return on Equity rose 98.0% to 0.0% in Q3 2024 year-over-year; TTM through Sep 2024 was 0.0%, a 98.0% increase, with the full-year FY2023 number at 0.22%, down 221.0% from a year prior.
- Return on Equity was 0.0% for Q3 2024 at Palvella Therapeutics, down from 0.05% in the prior quarter.
- In the past five years, Return on Equity ranged from a high of 1.29% in Q1 2023 to a low of 1.28% in Q2 2023.
- A 5-year average of 0.49% and a median of 0.48% in 2020 define the central range for Return on Equity.
- Peak YoY movement for Return on Equity: surged 233bps in 2023, then crashed -132bps in 2024.
- Palvella Therapeutics' Return on Equity stood at 0.89% in 2020, then fell by -11bps to 0.99% in 2021, then surged by 61bps to 0.38% in 2022, then surged by 219bps to 0.46% in 2023, then crashed by -101bps to 0.0% in 2024.
- Per Business Quant, the three most recent readings for PVLA's Return on Equity are 0.0% (Q3 2024), 0.05% (Q2 2024), and 0.03% (Q1 2024).